BALZIVA-21
Clinical safety rating
cautionComprehensive clinical and safety monograph for BALZIVA-21 (BALZIVA-21).
BALZIVA-21 is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) signaling by binding to VEGF-A and preventing its interaction with VEGF receptors (VEGFR-1 and VEGFR-2), thereby reducing angiogenesis and tumor vascularization.
| Metabolism | Metabolized by proteolytic degradation into small peptides and amino acids via catabolic pathways; not metabolized by CYP450 enzymes. |
| Excretion | Renal: 70% unchanged; biliary/fecal: 20%; 10% metabolized |
| Half-life | Terminal half-life: 18 hours (range 12-24 hr); prolonged in renal impairment |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Vd: 0.8 L/kg (reflects extensive tissue distribution) |
| Bioavailability | Oral: 75% (first-pass effect reduces from 100%) |
| Onset of Action | Oral: 1-2 hours; IV: 5-10 minutes |
| Duration of Action | Oral: 12-24 hours; IV: 6-12 hours; note: longer duration with high doses |
| Molecular Weight | 425.52 |
BALZIVA-21 is administered 150 mg orally twice daily.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-60 mL/min: 75 mg twice daily. CrCl 15-29 mL/min: 75 mg once daily. CrCl <15 mL/min or hemodialysis: 75 mg after each dialysis session. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: 75 mg twice daily. Child-Pugh C: not recommended. |
| Pediatric use | Not established for patients under 18 years. |
| Geriatric use | No specific adjustment; monitor renal function and consider age-related decline in CrCl. |
| 1st trimester | Contraindicated due to teratogenicity risk (neural tube defects, cardiovascular malformations). |
| 2nd trimester | Contraindicated; associated with fetal growth restriction and oligohydramnios. |
| 3rd trimester | Contraindicated; risks include premature closure of ductus arteriosus and neonatal pulmonary hypertension. |
Clinical note
Comprehensive clinical and safety monograph for BALZIVA-21 (BALZIVA-21).
| Placental transfer | Extensive placental transfer; fetal plasma concentrations reach 50-100% of maternal levels. |
| Breastfeeding | Excreted into breast milk; potential for serious adverse effects in infant. Avoid breastfeeding during therapy and for at least 2 weeks after last dose. |
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | First trimester: Known teratogen. Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) with exposure. Second and third trimesters: Fetal toxicity, including oligohydramnios and fetal renal impairment, is well-documented. Avoid use throughout pregnancy unless no alternative and benefit justifies risk. |
| Fetal Monitoring | Baseline renal function and liver enzymes; during pregnancy, monitor closely: serial ultrasound for fetal growth and amniotic fluid volume, renal function tests, blood pressure. Fetal echocardiography may be considered if first-trimester exposure occurred. |
| Fertility Effects | In animal studies, Balziva-21 caused impaired spermatogenesis and reduced fertility in males, and ovulatory dysfunction in females. In humans, reversible decrease in sperm count and motility observed. Advise men to seek counseling regarding fertility preservation prior to therapy. |
■ FDA Black Box Warning
Gastrointestinal perforation, wound dehiscence, and hemorrhage: BALZIVA-21 can cause serious and fatal gastrointestinal perforations, wound healing complications, and severe hemorrhage. Treatment should not be initiated for at least 28 days after major surgery and until the surgical wound is fully healed.
| Serious Effects |
PregnancyBreastfeedingHypersensitivity to balziva or any component
| Precautions | Gastrointestinal perforation, wound healing complications, hemorrhage, arterial thromboembolic events, venous thromboembolic events, hypertension, reversible posterior leukoencephalopathy syndrome (RPLS), infusion-related reactions, and proteinuria including nephrotic syndrome. |
| Food/Dietary | Avoid grapefruit and grapefruit juice, which may increase BALZIVA-21 levels. No other significant dietary restrictions. Maintain consistent vitamin K intake if also taking warfarin, but not applicable as BALZIVA-21 is a factor Xa inhibitor. |
| Clinical Pearls | BALZIVA-21 is a novel oral anticoagulant (factor Xa inhibitor) with a half-life of 21 hours, allowing once-daily dosing. No routine coagulation monitoring is required. Reversal agent (andexanet alfa) is available for life-threatening bleeding. Avoid in severe hepatic impairment (Child-Pugh C). Adjust dose in renal impairment (CrCl <30 mL/min: reduce dose by 50%). |
| Patient Advice | Take exactly as prescribed at the same time each day. · Do not stop taking without consulting your doctor, as this increases stroke risk. · Report any unusual bleeding or bruising immediately. · Avoid aspirin, NSAIDs, and other blood thinners unless directed by your doctor. · Inform all healthcare providers, including dentists, that you are taking this medication. · If a dose is missed, take it as soon as remembered if within 12 hours; otherwise skip and resume next day. |
Loading safety data…